Libor Havel - Researcher Profile | RDL Research Database

Publications

4 shown

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Leora Horn , Aaron S. Mansfield , Aleksandra Szczęsna +18 more

The addition of atezolizumab to chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer resulted in significantly longer overall survival and progress...

2018 New England Journal of Medicine 3263 citations

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok , Yi‐Long Wu , Iveta Kudaba +97 more

2019 The Lancet 3175 citations

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer , Karen L. Reckamp , Paul Baas +22 more

Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab tha...

2015 New England Journal of Medicine 8355 citations

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares , Mikhail Dvorkin , Yuanbin Chen +97 more

2019 The Lancet 2014 citations

Frequent Co-Authors

Researcher Info

h-index: 4
Publications: 5
Citations: 18,821
Institution: Fakultní nemocnice Bulovka

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0009-0007-9131-226X

Impact Metrics

h-index 4

h-index: Number of publications with at least h citations each.